T1	Participants 115 129	GERD patients.
T2	Participants 215 263	gastro-esophageal reflux disease (GERD) patients
T3	Participants 483 497	GERD patients.
T4	Participants 506 647	Forty-seven GERD patients randomized to endoscopic fundoplication (n = 32) or PPI therapy (n = 15), and 29 healthy controls were included
T5	Participants 877 903	impedance in GERD patients
T6	Participants 914 938	than in healthy controls
T7	Participants 1575 1596	baseline impedance in
